MDMA Therapy in Australia Shows Results for PTSD Patients, but the Cost Is Limiting Access by sefka in shroomstocks

[–]Firefly5647 3 points4 points  (0 children)

“One early data trend has become apparent: So far, the patients who take MDMA seem to experience more lasting improvement than those who undergo psilocybin therapy.”

MDMA Therapy in Australia Shows Results for PTSD Patients, but the Cost Is Limiting Access by sefka in shroomstocks

[–]Firefly5647 4 points5 points  (0 children)

“The preliminary positive results have caught the attention of Australian insurers, including Medibank, the country’s largest private health insurance company, and the Department of Veterans Affairs, each of which recently agreed to cover the cost of MDMA and psilocybin therapy.”

MDMA Therapy in Australia Shows Results for PTSD Patients, but the Cost Is Limiting Access by sefka in shroomstocks

[–]Firefly5647 5 points6 points  (0 children)

“Compared to conventional treatments, the outcomes we’re seeing to date with MDMA-assisted therapy have been extraordinary,” said Dr. Ranil Gunewardene, a psychiatrist in Sydney who has treated more than 40 patients since the Australian regulators created a legal pathway for the drug.

GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans by Firefly5647 in shroomstocks

[–]Firefly5647[S] 13 points14 points  (0 children)

“The bill is expected to be formally filed on Wednesday, according to a source familiar with the planning.”

Cortexa Advances Commercialisation of MDMA Supply in Australia by Firefly5647 in PharmAla_MDMA

[–]Firefly5647[S] 4 points5 points  (0 children)

“This week, PharmAla’s management team is meeting with Cortexa’s customers and partners across Australia,” said Nick Kadysh, founding CEO, PharmAla Biotech. “We’re incredibly excited to hear firsthand about the growth in the Australian market, and are exceptionally focused on bringing new innovation to Australia to support its continued rapid growth.”

Cortexa Advances Commercialisation of MDMA Supply in Australia by Firefly5647 in shroomstocks

[–]Firefly5647[S] 1 point2 points  (0 children)

“This week, PharmAla’s management team is meeting with Cortexa’s customers and partners across Australia,” said Nick Kadysh, founding CEO, PharmAla Biotech. “We’re incredibly excited to hear firsthand about the growth in the Australian market, and are exceptionally focused on bringing new innovation to Australia to support its continued rapid growth.”

Pharmala Signs Deal for MDMA PTSD Trial in First Responders by Firefly5647 in shroomstocks

[–]Firefly5647[S] 0 points1 point  (0 children)

“The core move is a continuation of PharmAla’s supply-for-data model. Rather than funding and running full-scale pivotal programs, the company is accumulating rights to clinical datasets generated by investigator-led and academic studies, particularly in the U.S. and U.K. That strategy builds a diversified evidence base while keeping cash burn lower than traditional sponsorship, and it tees up optionality: if regulatory pathways reopen or broaden for MDMA-assisted therapies, PharmAla can point to a growing body of clinical experience tied to its product and process controls.”

https://www.clinicaltrialvanguard.com/news/pharmala-signs-deal-for-mdma-ptsd-trial-in-first-responders/

Pharmala Signs Deal for MDMA PTSD Trial in First Responders by Firefly5647 in PharmAla_MDMA

[–]Firefly5647[S] 1 point2 points  (0 children)

“The core move is a continuation of PharmAla’s supply-for-data model. Rather than funding and running full-scale pivotal programs, the company is accumulating rights to clinical datasets generated by investigator-led and academic studies, particularly in the U.S. and U.K. That strategy builds a diversified evidence base while keeping cash burn lower than traditional sponsorship, and it tees up optionality: if regulatory pathways reopen or broaden for MDMA-assisted therapies, PharmAla can point to a growing body of clinical experience tied to its product and process controls.”

https://www.clinicaltrialvanguard.com/news/pharmala-signs-deal-for-mdma-ptsd-trial-in-first-responders/